

CLAIMS:

1. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2873), or a salt thereof.

2. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2752), or a salt thereof.

3. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 765), or a salt thereof.

4. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 1949), or a salt thereof.

5. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2751), or a salt thereof.


6. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2866), or a salt thereof.


7. The modified oligonucleotide of any of claims 1-6, which is the sodium salt or the potassium salt.

8. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2873).

9. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 2752).

10. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 765).

11. A modified oligonucleotide according to the following chemical structure:




(SEQ ID NO: 1949).

12. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2751).

13. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2866).

14. A pharmaceutical composition comprising the modified oligonucleotide of any one of claims 1-6 and a pharmaceutically acceptable diluent.

15. The pharmaceutical composition of claim 14, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

16. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and artificial cerebrospinal fluid.

17. A pharmaceutical composition comprising the modified oligonucleotide of any one of claims 8-13 and a pharmaceutically acceptable diluent.

18. The pharmaceutical composition of claim 17, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

19. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and artificial cerebrospinal fluid.

20. A compound comprising a modified oligonucleotide according to the following chemical notation: $A_{es}{}^{m}C_{eo}{}^{m}C_{eo}A_{eo}T_{eo}T_{ds}T_{ds}T_{ds}G_{ds}A_{ds}{}^{m}C_{ds}{}^{m}C_{ds}T_{ds}T_{ds}{}^{m}C_{ds}T_{eo}T_{eo}A_{es}G_{es}{}^{m}C_{e}$ (SEQ ID NO: 2873), wherein:

A = an adenine nucleobase,
mC = a 5-methyl cytosine nucleobase,
G = a guanine nucleobase,
T = a thymine nucleobase,
e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,
d = a 2'-β-D-deoxyribosyl sugar moiety,
s = a phosphorothioate internucleoside linkage, and
o = a phosphodiester internucleoside linkage.

21. A compound comprising a modified oligonucleotide according to the following chemical notation: $T_{es}T_{eo}{}^{m}C_{eo}A_{eo}{}^{m}C_{eo}{}^{m}C_{eo}A_{ds}T_{ds}T_{ds}T_{ds}G_{ds}A_{ds}{}^{m}C_{ds}{}^{m}C_{ds}T_{ds}T_{eo}{}^{m}C_{es}T_{es}T_{e}$ (SEQ ID NO: 2752), wherein:

A = an adenine nucleobase,
mC = a 5-methyl cytosine nucleobase,
G = a guanine nucleobase,
T = a thymine nucleobase,
e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,
d = a 2'-β-D-deoxyribosyl sugar moiety,
s = a phosphorothioate internucleoside linkage, and
o = a phosphodiester internucleoside linkage.

22. A compound comprising a modified oligonucleotide according to the following chemical notation: $G_{es}{}^{m}C_{eo}A_{eo}T_{eo}A_{eo}{}^{m}C_{eo}{}^{m}C_{ds}{}^{m}C_{ds}A_{ds}G_{ds}G_{ds}G_{ds}T_{ds}A_{ds}G_{ds}G_{ds}A_{eo}T_{es}T_{es}{}^{m}C_{e}$ (SEQ ID NO: 765), wherein:

A = an adenine nucleobase,
mC = a 5-methyl cytosine nucleobase,
G = a guanine nucleobase,
T = a thymine nucleobase,
e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,
d = a 2'-β-D-deoxyribosyl sugar moiety,
s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

23. A compound comprising a modified oligonucleotide according to the following chemical notation: $^{m}C_{es}A_{eo}T_{eo}{}^{m}C_{eo}A_{eo}T_{ds}G_{ds}A_{ds}T_{ds}{}^{m}C_{ds}T_{ds}T_{ds}G_{ds}G_{ds}T_{ds}A_{eo}A_{eo}G_{es}G_{es}{}^{m}C_{e}$ (SEQ ID NO: 1949), wherein:

A = an adenine nucleobase,
mC = a 5-methyl cytosine nucleobase,
G = a guanine nucleobase,
T = a thymine nucleobase,
e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,
d = a 2'-β-D-deoxyribosyl sugar moiety,
s = a phosphorothioate internucleoside linkage, and
o = a phosphodiester internucleoside linkage.

24. A compound comprising a modified oligonucleotide according to the following chemical notation: $T_{es}{}^{m}C_{eo}A_{eo}{}^{m}C_{eo}{}^{m}C_{eo}A_{eo}T_{ds}T_{ds}T_{ds}T_{ds}G_{ds}A_{ds}{}^{m}C_{ds}{}^{m}C_{ds}T_{ds}T_{ds}{}^{m}C_{eo}T_{es}T_{es}A_{e}$ (SEQ ID NO: 2751), wherein:

A = an adenine nucleobase,
mC = a 5-methyl cytosine nucleobase,
G = a guanine nucleobase,
T = a thymine nucleobase,
e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,
d = a 2'-β-D-deoxyribosyl sugar moiety,
s = a phosphorothioate internucleoside linkage, and
o = a phosphodiester internucleoside linkage.

25. A compound comprising a modified oligonucleotide according to the following chemical notation: $A_{es}{}^{m}C_{eo}G_{eo}{}^{m}C_{es}A_{ds}A_{ds}T_{ds}G_{ds}T_{ds}A_{ds}T_{ds}{}^{m}C_{ds}A_{eo}G_{eo}G_{eo}{}^{m}C_{es}A_{es}A_{e}$ (SEQ ID NO: 2866), wherein:

A = an adenine nucleobase,
mC = a 5-methyl cytosine nucleobase,
G = a guanine nucleobase,
T = a thymine nucleobase,
e = a 2'-$O(CH_2)_2OCH_3$ β-D-ribosyl sugar moiety,
d = a 2'-β-D-deoxyribosyl sugar moiety,
s = a phosphorothioate internucleoside linkage, and
o = a phosphodiester internucleoside linkage.

26. A pharmaceutical composition comprising the compound of any one of claims 20-25, and a pharmaceutically acceptable diluent.

27. The pharmaceutical composition of claim 26, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

28. The pharmaceutical composition of claim 27, wherein the pharmaceutical composition consists essentially of the compound and artificial cerebrospinal fluid.

29. The compound of any one of claims 20-25, comprising the modified oligonucleotide covalently linked to a conjugate group.

30. A pharmaceutical composition comprising the compound of claim 29, and a pharmaceutically acceptable diluent.

31. The pharmaceutical composition of claim 30, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

32. The pharmaceutical composition of claim 31, wherein the pharmaceutical composition consists essentially of the compound and artificial cerebrospinal fluid.